ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12...115116117118119120121122123124125...129130»
  • ||||||||||  ivermectin oral / Generic mfg., doxycycline delayed-release / Generic mfg.
    New P2 trial, Combination therapy:  Trial of Combination Therapy to Treat COVID-19 Infection (clinicaltrials.gov) -  Jul 21, 2020   
    P2,  N=300, Not yet recruiting, 
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] STRONGYLOIDES STERCOLARIS WITH GASTRIC INVOLVEMENT AND COMPLICATED WITH SIADH: AN UNUSUAL DIAGNOSIS TO CONSIDER IN IMMUNOSUPPRESSED PATIENTS WITH HYPEREMESIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_5579;    
    Ivermectin is initiated with clinical improvement. Strongyloides stercolaris is a human parasite, endemic in temperate regions.1-3 The lifecycle starts when larvae penetrate the skin and migrate to the lungs.1-3 They ascend through the bronchial tree and reach the digestive tract, where they invade the small bowel and live in the crypts, mainly in duodenum and upper jejunum.1,3 Infection in immunocompetent hosts is self-limited but immunossupression lead to hyperinfection syndrome and disseminated disease.1,2 Hyperinfection occurs when the lifecycle is augmented and disseminated strongyloidiasis when the parasite extend the traditional lifecycle and invade other organs.1,2,4 However, the involvement of stomach has rarely been reported.2 Hematologic malignancies, transplantation, immunosuppressive drugs and HIV are risk factors for hyperinfection.1 Symptoms are non-specific, and it is frequently asymptomatic.1-3 Malabsorption, gastrointestinal bleeding, obstruction, SIADH and sepsis have been described.1-3 The non-specific clinical and imaging features and the low sensitivity of routine parasite tests make the diagnosis delayed.5 Definitive diagnosis is made on direct visualization of larvae in stool, intestinal aspirates or biopsies.5
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] STRONGYLOIDES STERCOLARIS WITH GASTRIC INVOLVEMENT AND COMPLICATED WITH SIADH: AN UNUSUAL DIAGNOSIS TO CONSIDER IN IMMUNOSUPPRESSED PATIENTS WITH HYPEREMESIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_3603;    
    Ivermectin is initiated with clinical improvement. Strongyloides stercolaris is a human parasite, endemic in temperate regions.1-3 The lifecycle starts when larvae penetrate the skin and migrate to the lungs.1-3 They ascend through the bronchial tree and reach the digestive tract, where they invade the small bowel and live in the crypts, mainly in duodenum and upper jejunum.1,3 Infection in immunocompetent hosts is self-limited but immunossupression lead to hyperinfection syndrome and disseminated disease.1,2 Hyperinfection occurs when the lifecycle is augmented and disseminated strongyloidiasis when the parasite extend the traditional lifecycle and invade other organs.1,2,4 However, the involvement of stomach has rarely been reported.2 Hematologic malignancies, transplantation, immunosuppressive drugs and HIV are risk factors for hyperinfection.1 Symptoms are non-specific, and it is frequently asymptomatic.1-3 Malabsorption, gastrointestinal bleeding, obstruction, SIADH and sepsis have been described.1-3 The non-specific clinical and imaging features and the low sensitivity of routine parasite tests make the diagnosis delayed.5 Definitive diagnosis is made on direct visualization of larvae in stool, intestinal aspirates or biopsies.5
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] STRONGYLOIDES STERCOLARIS WITH GASTRIC INVOLVEMENT AND COMPLICATED WITH SIADH: AN UNUSUAL DIAGNOSIS TO CONSIDER IN IMMUNOSUPPRESSED PATIENTS WITH HYPEREMESIS (Poster Exhibition) -  Jul 19, 2020 - Abstract #UEGW2020UEGW_1619;    
    Ivermectin is initiated with clinical improvement. Strongyloides stercolaris is a human parasite, endemic in temperate regions.1-3 The lifecycle starts when larvae penetrate the skin and migrate to the lungs.1-3 They ascend through the bronchial tree and reach the digestive tract, where they invade the small bowel and live in the crypts, mainly in duodenum and upper jejunum.1,3 Infection in immunocompetent hosts is self-limited but immunossupression lead to hyperinfection syndrome and disseminated disease.1,2 Hyperinfection occurs when the lifecycle is augmented and disseminated strongyloidiasis when the parasite extend the traditional lifecycle and invade other organs.1,2,4 However, the involvement of stomach has rarely been reported.2 Hematologic malignancies, transplantation, immunosuppressive drugs and HIV are risk factors for hyperinfection.1 Symptoms are non-specific, and it is frequently asymptomatic.1-3 Malabsorption, gastrointestinal bleeding, obstruction, SIADH and sepsis have been described.1-3 The non-specific clinical and imaging features and the low sensitivity of routine parasite tests make the diagnosis delayed.5 Definitive diagnosis is made on direct visualization of larvae in stool, intestinal aspirates or biopsies.5
  • ||||||||||  ivermectin / Generic mfg.
    IVERMECTIN!!!! (Twitter) -  Jul 16, 2020   
  • ||||||||||  ivermectin / Generic mfg., levamisole / Generic mfg.
    Journal:  Sensory cilia as the Achilles heel of nematodes when attacked by carnivorous mushrooms. (Pubmed Central) -  Jul 16, 2020   
    This cilia-dependent predatory mechanism is evolutionarily conserved in Pristionchus pacificus, a nematode species estimated to have diverged from C. elegans 280 to 430 million y ago. Thus, P. ostreatus exploits a nematode-killing mechanism that is distinct from widely used anthelmintic drugs such as ivermectin, levamisole, and aldicarb, representing a potential route for targeting parasitic nematodes in plants, animals, and humans.
  • ||||||||||  clarithromycin / Generic mfg., rifampicin / Generic mfg.
    [VIRTUAL] In vitroex vivo activity of Avermectin derivatives against clarithromycin resistant Mycobacterium avium. (Pre-congress content) -  Jul 15, 2020 - Abstract #ERS2020ERS_968;    
    All these compounds also showed activity against intracellular M. avium within THP-1 macrophages. Moreover, intracellular activity of these five compounds were much higher than Ivermectin itself.Therefore, the present results strongly indicated that these five avermectin derivatives, despite a member of macrolide, have novel antibiotic targets not shared by clarithromycin.